Skip to main content
Top

12-20-2017 | Semaglutide | News

News in brief

Semaglutide at least equivalent to exenatide on weekly schedule

print
PRINT
insite
SEARCH

medwireNews: The SUSTAIN 3 findings have been published in Diabetes Care, showing that semaglutide given once weekly is at least as effective as exenatide extended-release, with a similar safety profile.

The investigators, led by Andrew Ahmann (Oregon Health & Science University, Portland, USA), in fact found that semaglutide 1.0 mg produced a larger fall in glycated hemoglobin (HbA1c) levels, of 1.5% (16.8 mmol/mol) in 404 patients randomly assigned to receive it for 56 weeks.

Exenatide 2.0 mg produced a significantly smaller reduction, of 0.9% (10 mmol/mol) among 405 patients, but the researchers note that larger reductions occurred in other trials of the medication and say that they “cannot exclude the possibility that the open-label design of the trial and the more complex device system used to administer exenatide [extended-release] contributed to the lower performance of this treatment.”

Adverse events occurred at a similar rate in both groups, but gastrointestinal events were more common with semaglutide than exenatide, particularly nausea at 22.3% versus 11.9%, whereas the reverse was true for injection site reactions, with nodules occurring in 0.0% versus 12.1%.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »